FeesSafety
Pluang+

Anthropic's IPO may soar if AI demand grows despite a lower initial valuation forecast.

Market News
19 Nov 2026, 02:21 WIB
The Motley Fool
View Source
Bullish
Anthropic's IPO may soar if AI demand grows despite a lower initial valuation forecast.

Anthropic is launching its IPO with an initial list price of $83, but shares may trade higher on the open market due to strong demand. Although its valuation forecast has dropped from $2 trillion earlier this year due to waning AI investment enthusiasm, the company’s rapid revenue growth—12 times year-over-year to $17 billion in Q3—suggests long-term potential. Investors should consider buying for the long haul, as Anthropic aims to be a major player in the AI sector with significant growth opportunities ahead.

Anthropic's IPO launch is the subject, providing context for readers interested in technology stocks. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 19, 2026 06:42 WIB: out of 150 priced US stocks, 74 rose and 75 fell. Notable movers include AKAM at USD 93.37 with a 10.31% gain and ZS at USD 203.55 with a 9.91% gain, while KLTR dropped 11.68% to USD 1.21.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
1 hour ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
1 hour ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
1 hour ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
1 hour ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App